Lin Shao-Lee
Chief Executive Officer
Lin Shao-Lee has filed 4 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Oct 15, 2026.
On the most recent filing, Lin Shao-Lee is listed as Chief Executive Officer at Cue Biopharma, Inc. Inside the rolling window, Lin Shao-Lee reported no open-market purchases and 3 open-market sales totaling $1.9M in CUE. The largest disclosed transaction in the window is a sale of 40,000 CUE shares on Aug 12, 2026, worth $1.1M.
Companies traded
Other insiders at CUE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.9M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lin Shao-Lee made?
Lin Shao-Lee has filed 4 SEC Form 4 filings (10 transaction rows) across 1 company since 2026.
Which companies does Lin Shao-Lee trade?
Lin Shao-Lee has filed SEC Form 4 disclosures for 1 company, including CUE.
When was Lin Shao-Lee's most recent SEC Form 4 filing?
Lin Shao-Lee's most recent SEC Form 4 filing on Tracefour is dated Oct 15, 2026.
What is Lin Shao-Lee's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lin Shao-Lee is listed as Chief Executive Officer.
What is Lin Shao-Lee's total buy and sell value in the current window?
Inside the rolling retention window, Lin Shao-Lee bought $0 and sold $1.9M based on SEC Form 4 filings.
What was Lin Shao-Lee's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 40,000 CUE shares on 2026-08-12, worth $1.1M, per SEC Form 4 filings.